Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?
Search

May 2026

Steep Sentence Underscores Scrutiny of Genetic Testing

Laboratory Compliance /

The sentencing tied to a $522 million genetic testing fraud scheme is more than just the latest fraud headline for clinical laboratory professionals. Instead, it serves as another warning that federal scrutiny surrounding genetic testing is continuing and unlikely to ease anytime soon. The US Department of Justice (DOJ) announced prison sentences for two lab […]

To access this post, you must purchase The Dark Report.

Steep Sentence Underscores Scrutiny of Genetic Testing Read More »

Labs Looking at Cash-Based Options Face Complexity

Clinical Laboratory Trends /

Given all the challenges of dealing with payers, many clinical laboratories find themselves tempted by the idea of offering cash-based business lines such as direct-to-consumer (DTC) testing. The patient pays up front and undergoes the test, and the lab banks the income without the hassles of filing a claim and awaiting reimbursement. But labs should

To access this post, you must purchase The Dark Report.

Labs Looking at Cash-Based Options Face Complexity Read More »

Astorg Makes Billion-Dollar Bet on Microbiology Testing

In Vitro Diagnostics /

Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to close in the second half of 2026, pending regulatory approvals. The divestiture

To access this post, you must purchase The Dark Report.

Astorg Makes Billion-Dollar Bet on Microbiology Testing Read More »

Behind the Cat-and-Mouse Game of Lab Reimbursement

Laboratory Billing /

Financial relationships between clinical laboratories and commercial payers have evolved into a high-stakes, technological tug-of-war. For nearly a decade, the clinical laboratory industry has wrestled with the provisions of the Protecting Access to Medicare Act (PAMA). While repeated legislative delays of PAMA-mandated cuts to lab test reimbursement rates have offered independent and hospital laboratories temporary

To access this post, you must purchase The Dark Report.

Behind the Cat-and-Mouse Game of Lab Reimbursement Read More »

Expect RESULTS Act Vote by the End of the Year

TDR Insider /

Evidence at the 2026 Executive War College suggests a coming push in clinical lab advocacy, focusing on the RESULTS Act to establish a permanent, database-driven reimbursement model. Simultaneously, federal regulators have floated the idea of heightened scrutiny of genetic test spending, signaling that while lab test reimbursement rates may stabilize, compliance oversight could enter a

To access this post, you must purchase The Dark Report.

Expect RESULTS Act Vote by the End of the Year Read More »

May 26, 2026, Intelligence: Late-Breaking Lab News

Late Breaking Lab News /

UnitedHealthcare is expanding rural healthcare initiatives that could provide operational relief for clinical laboratories in underserved communities. The effort focuses on improving cash flow, reducing administrative burdens, and strengthening financial stability for rural hospitals and providers. A key component involves accelerating Medicare Advantage reimbursements for approximately 1,500 rural hospitals and all critical access hospitals nationwide

To access this post, you must purchase The Dark Report.

May 26, 2026, Intelligence: Late-Breaking Lab News Read More »

Risk of Complacency May Be the Biggest Threat

Commentary and Opinion by R. Lewis Dark /

Prevailing sentiment at the recent Executive War College suggests a long-overdue legislative reprieve is within reach, but experienced clinical laboratory leaders know better than to mistake momentum on Capitol Hill for a signed bill. Our lead story reflects the optimism surrounding the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which boasts

To access this post, you must purchase The Dark Report.

Risk of Complacency May Be the Biggest Threat Read More »

Expect RESULTS Act Vote by End of the Year

Laboratory Billing /

CEO SUMMARY: Evidence at the 2026 Executive War College suggests a coming push in clinical lab advocacy, focusing on the RESULTS Act to establish a permanent, database-driven reimbursement model. Simultaneously, federal regulators have floated the idea of heightened scrutiny of genetic test spending, signaling that while lab test reimbursement rates may stabilize, compliance oversight could

To access this post, you must purchase The Dark Report.

Expect RESULTS Act Vote by End of the Year Read More »

Examining Roche’s Deal to Acquire PathAI

Digital Pathology /

CEO SUMMARY: At first glance, Roche’s announcement that it had bought digital pathology and AI firm PathAI could be seen as a narrowing of options for clinical laboratories and pathology practices. However, insider Lisa-Jean Clifford says labs have long had access to digital pathology integration features that Roche touted, making the context of the PathAI

To access this post, you must purchase The Dark Report.

Examining Roche’s Deal to Acquire PathAI Read More »

Positioning the Clinical Lab as a Strategic Powerhouse

TDR Insider /

The 31st Annual Executive War College in New Orleans showcased speakers who have re-imagined the diagnostic laboratory’s role from back-office utility to a primary driver of system-wide strategy and clinical excellence. A consistent theme came up during dozens of sessions at the conference: Clinical laboratories that lead integration efforts will define their own role in

To access this post, you must purchase The Dark Report.

Positioning the Clinical Lab as a Strategic Powerhouse Read More »

;